Research programme: antibacterial therapeutics - Entasis Therapeutics

Drug Profile

Research programme: antibacterial therapeutics - Entasis Therapeutics

Alternative Names: NBP programme

Latest Information Update: 24 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AstraZeneca
  • Developer Entasis Therapeutics
  • Class Antibacterials; Small molecules
  • Mechanism of Action Penicillin-binding protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Gram-negative infections

Most Recent Events

  • 12 Mar 2018 Entasis Therapeutics plans a phase I trial for Gram-negative infections (In volunteers) in Australia in April 2018 (ACTRN12618000350224p)
  • 07 Jul 2015 Research programme: antibacterials - Entasis Therapeutics is available for licensing as of 07 Jul 2015. http://www.entasistx.com/partnering/
  • 01 Jul 2015 Preclinical trials in Gram-negative infections in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top